Among drugs for the consequences of chemo, those with the highest profile are Amgen Inc.'s erythropoietin stimulating agents, Epogen (epoetin alfa) and Aranesp (darbepoetin alfa), and Ortho Biotech Products LP's Procrit (epoetin alfa) - all lately dogged by safety concerns that have led to label changes and lessened reimbursements due to concerns about safety. (BioWorld Financial Watch)